GleamWall
中文EN

LEXX Lexaria Bioscience Corp.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1348362 · Fiscal year ends 08/31

Financial factors as of 2026-05-31 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-68.5%
TTM net income YoY32.1%
TTM EPS YoY50.0%
Revenue 3-yr CAGR-14.2%
Net income 3-yr CAGR—

Margins

Gross margin100.0%
Operating margin-3,973.2%
Net margin-3,985.6%
FCF margin-3,848.6%
EBITDA margin-3,960.4%

Returns

ROE-150.3%
ROA-134.2%
ROIC (approx.)-553.9%
Asset turnover0.03x

Leverage & solvency

Liabilities / assets9.1%
Debt / equity0.00x
Current ratio10.60x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.96x
Accruals ratio-5.3%
Payout ratio—
Capex / revenue21.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-08-31FY20242024-08-31
Income statement
Revenue$705,923$464,278
Cost of revenue$2,720$4,822
Gross profit$703,203$459,456
R&D expense$8.24M$2.36M
SG&A expense$4.35M$3.85M
Operating income-$11.88M-$5.75M
Interest expense—$7,760
Pretax income-$11.91M-$5.81M
Net income-$11.90M-$5.80M
EBITDA-$11.83M-$5.71M
EPS (diluted)-0.66-0.47
Weighted avg. shares (diluted)18.00M12.38M
Banking
Net interest income—$14,311
Balance sheet
Cash & equivalents$1.80M$6.50M
Short-term investments$143,267$55,807
Receivables$368,358$154,477
Current assets$3.47M$7.90M
PP&E, net$228,129$254,709
Intangibles$307,818$516,676
Total assets$4.18M$8.87M
Current liabilities$1.49M$1.10M
Total liabilities$1.57M$1.21M
Shareholders' equity$2.99M$8.04M
Shares outstanding19.56M19.56M
Cash flow statement
Operating cash flow-$10.45M-$4.96M
Capital expenditure$24,646$43,014
Free cash flow-$10.48M-$5.00M
Investing cash flow-$243,019-$188,605
Financing cash flow$6.05M$10.32M
Depreciation & amortization$51,225$42,448
Stock-based compensation$859,494$492,236

Free plan shows the latest 2 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.